CDC25磷酸酶抑制剂研究进展(2008～2014年)  

Recent advances in CDC25 phosphatase inhibitors as potential agents for cancer therapy( 2008-2014)

作　　者：宋宇宁[1,2] 康东伟[1] 张庆柱[2] 展鹏[1] 刘新泳[1] 

机构地区：[1]山东大学药学院药物化学研究所,山东济南250012 [2]山东大学药学院新药药理研究所化学生物学教育部重点实验室,山东济南250012

出　　处：《中国药物化学杂志》2015年第1期54-65,共12页Chinese Journal of Medicinal Chemistry

基　　金：国家自然科学基金项目(81102320;81273354);山东省科技发展计划项目(2014GSF118012);中国博士后科学基金第五批特别资助项目(2012T50584)

摘　　要：细胞分裂周期蛋白CDC25磷酸酶与细胞周期依赖性蛋白的调控以及细胞增殖密切相关,且在许多肿瘤中过度表达,CDC25磷酸酶已经成为很有前景的癌症治疗靶标。许多结构多样的天然产物及合成小分子化合物被证实是特异性的CDC25磷酸酶和抗肿瘤先导化合物,本文对该领域的研究新进展进行综述。Cell division cycle （CDC） 25 protein phosphatases represent an attractive potential therapeutic an- tiproliferative target for small molecule intervention because of its essential roles in positively regulating cyc- lin dependent kinases （CDKs） and cell proliferation, as well as its overexpression frequently observed in many human tumors. Over the past few years, many natural and synthetic molecules with different structural features targeting CDC25 activity have been reported. These compounds provide a new starting point for fur- ther structural optimization, which may afford new discoveries of inhibitory agents against the CDC25 phos- phatases. Hence, this review aims to provide an overview of recent developments on design of CDC25 phos- phatase inhibitors since 2008.

关 键 词：CDC25磷酸酶 抗肿瘤化合物 药物设计 杂环化合物 天然产物 

分 类 号：R943[医药卫生—药剂学]